Overview

A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
To generate additional long-term safety and efficacy data on flibanserin in premenopausal women and establish long-term safety and tolerability of flibanserin in naturally postmenopausal women with Hypoactive Sexual Desire Disorder who have completed a prior clinical trial of flibanserin (Trial 511.130, 511.147, or 511.156).
Phase:
Phase 3
Details
Lead Sponsor:
Sprout Pharmaceuticals, Inc